ING Group’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

ING Group’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-5,325	Closed	-$3.91M	–	764
2015 Q1	$3.91M	Sell	5,325 -34,777	-87%	-$26.1M	0.02%	435
2014 Q4	$31.8M	Buy	+40,102	New	+$21.6M	0.15%	148

Other funds holding TTPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ING Group's TTPH Position: Q2 2015 in Review

ING Group sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q2 2015, closing a stake of 5,325 shares — an estimated $3.91M sold.

ING Group first reported a position in TTPH in Q4 2014 and held it in 2 quarters. The position peaked at $31.8M in Q4 2014. 139 funds tracked by Wall St. Rank hold TTPH as of Q2 2015.

ING Group reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
ING Group sold 5,325 Tetraphase Pharmaceuticals, Inc. shares in Q2 2015, an estimated $3.91M.
ING Group first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2014 and held it in 2 quarters.
ING Group's Tetraphase Pharmaceuticals, Inc. position peaked at $31.8M in Q4 2014.
139 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q2 2015.

Based on ING Group's 13F filing for Q2 2015, filed 10 Aug 2015.